Cell-free DNA as a prognostic biomarker in patients with COVID-19 disease
- Conditions
- cfDNA in patients with COVID-19
- Registration Number
- DRKS00031641
- Lead Sponsor
- niversitätsmedizin Mainz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
COVID-19 disease
Exclusion Criteria
- pregnancy
- breast feeding women
- Blood sample taken too late
- medication (Remicade, Tofacitinib)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation of cfDNA with disease severity during its course, as measured by the WHO clinical progression scale.
- Secondary Outcome Measures
Name Time Method - Mortality<br>-pre-existing conditions <br>-organ replacement procedures (ECMO, ventilation, dialysis, catecholamines)<br>- standard laboratory parameters (CRP, PCT, D-dimer, LDH, ...)<br>- duration of hospital stay<br>- duration of ICU stay